 The BCR-ABL1 fusion gene, the causative lesion of chronic myeloid leukemia (CML) in >95 % of newly presenting patients, offers both a therapeutic and diagnostic target.     ///    Real-time quantification assay to monitor BCR-ABL1 transcripts in chronic myeloid leukemia.. 